2025-522113-35-00
尚未招募
2 期
A Phase 2a, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Multiple Subcutaneous Doses of TRIV-509 in Adults with Moderate to Severe Atopic Dermatitis
Triveni Bio Inc.5 个研究点 分布在 1 个国家目标入组 11 人开始时间: 2025年12月9日最近更新:
概览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- Triveni Bio Inc.
- 入组人数
- 11
- 试验地点
- 5
- 主要终点
- 1. Percentage of participants with improvement of AD at Week 16
概览
简要总结
To assess the efficacy of TRIV-509 administered by SC injection for 12 weeks in adults with moderate to severe AD
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Aged ≥ 18 to ≤75 years, inclusive, at the time of signing the informed consent.
- •Has chronic AD
- •Has had no significant flares in AD for at least 28 days prior to Screening, in the opinion of the Investigator.
- •Has moderate to severe, active, and symptomatic AD
- •Meets Pruritus NRS severity score requirements at baseline.
- •Has required systemic therapy to achieve adequate control of AD OR cannot use topical medications OR has a history of inadequate response to topical medications for at least 28 days, as judged by the Investigator.
- •Body weight ≥ 40 kg (88.2 pounds) at Screening
- •A participant is eligible to participate if not pregnant or breastfeeding, and one of the following conditions applies: a. Is of nonchildbearing potential (NCBP) as defined in Appendix 4: Contraceptive and Barrier Guidance. OR b. Is of childbearing potential (CBP) and has a negative serum pregnancy test at Screening and a negative urine pregnancy test before the first dose of study intervention on Day 1 AND must agree to use a contraceptive method that is highly effective (with a failure rate of < 1% per year), preferably with low user dependency, as described in Appendix 4: Contraceptive and Barrier Guidance until EOS or for at least 24 weeks after the last dose of study intervention, whichever is later. Note: If the form of contraception used is a hormonal contraceptive, the participant must be on a stable dose of the hormonal contraceptive from weeks before Day 1 until the EOS or for at least 24 weeks after the last study intervention administration, whichever is longer. AND agrees not to donate ova until the EOS or for at least 24 weeks after the last dose of study intervention, whichever is later.
- •Male participants of reproductive potential must a. refrain from donating sperm or fathering a child from Day 1 (first dose of study intervention) until at least 24 weeks after the last study intervention administration, AND b. must agree to use an additional highly effective contraceptive method with a failure rate of <1% per year, preferably with low user dependency, as described in Appendix 4: Contraceptive and Barrier Guidance, when having sexual intercourse with a partner of CBP until EOS or for at least 24 weeks after the last dose of study intervention, whichever is later. Note: If the female partner of a male participant uses any hormonal contraceptive, the female partner must be on a stable dose of hormonal contraceptive for ≥4 weeks before Day 1 until EOS or for at least 24 weeks after the last study intervention administration, whichever is longer.
- •Signed informed consent as described in Section 10.1.3, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
排除标准
- •Severe or uncontrolled medical conditions (including but not limited to cardiovascular, respiratory, endocrine, neurologic, immunologic, or psychiatric disease) that would put the participant at undue risk for participation in a clinical trial or compromise clinical trial interpretation.
- •History of cancer or lymphoproliferative disease within 5 years before Day
- •Participants with successfully treated nonmetastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix remain eligible.
- •Had a major surgery within 8 weeks before Screening or has a major surgery planned during the study.
- •Evidence of an active and/or concurrent dermatologic condition (e.g., seborrheic dermatitis, psoriasis, acute allergic contact dermatitis) that would interfere with the Investigator or participant-driven evaluations of AD.
- •Active chronic or acute infection that requires treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 14 days before Day 1, or superficial skin infection (if requiring topical or systemic antibiotics) within 14 days before Day
- •History of active tuberculosis (TB), positive QuantiFERON-Gold TB test, or two indeterminate QuantiFERON-Gold TB tests. If the participant has a history of latent TB and/or positive QuantiFERON-Gold TB test but no history of active TB or signs/symptoms consistent with active TB with a regiment and duration consistent with country-specific guidelines before Screening, the participant remains eligible. If the first QuantiFERON-Gold TB test is indeterminant but the second is negative, the participant remains eligible.
- •Positive human immunodeficiency virus (HIV) antibody test.
- •Positive hepatitis B surface antigen (HBsAg) OR hepatitis B core antibody (anti-Hbc) test; for positive hepatitis B core antibody only, if reflex hepatitis B surface antibody (anti-Hbs) is positive AND hepatitis B DNA PCR is negative, participant remains eligible. Refer to Section 10.5 for additional guidance on hepatitis B testing.
- •Positive hepatitis C antibody test result with reflex positive HCV RNA at Screening. Note: For participants previously treated for hepatitis C, treatment must have been completed at least 84 days prior to Screening, with negative HCV RNA documented at that time and no positive RNA results thereafter.
结局指标
主要结局
1. Percentage of participants with improvement of AD at Week 16
1. Percentage of participants with improvement of AD at Week 16
次要结局
- 1. Percentage of participants with improvement of AD at Week 16 5. Percentage of participants with TEAEs 6. Percentage of participants with SAEs 7. Changes in vital signs, ECG parameters, and safety laboratory values 8. Single-dose and multiple-dose PK parameters 9. Percentage of participants with anti-TRIV-509 antibodies
研究者
Triveni Bio, Inc.
Scientific
Triveni Bio Inc.
研究点 (5)
Loading locations...
相似试验
已完成
不适用
This is a study to evaluate dose-flexibility of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis2023-504869-23-00AbbVie Deutschland GmbH & Co. KG272
招募中
不适用
TCR-engineered T Cells (NW-101C) in Patients With Solid Malignant TumorsNCT07266298Neowise Biotechnology24
尚未招募
不适用
QTc Assessment in a Single-Dose Study of Hydronidone CapsulesNCT07263152Beijing Continent Pharmaceutical Co, Ltd.48
招募中
不适用
A Phase I Study of WTX212A Monotherapy or in Combination With Radiotherapy in Patients With Advanced Solid TumorsNCT07269899Sun Yat-sen University12
招募中
3 期
A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract CancerNCT07265674J-Pharma Co., Ltd.480